Novel sst4-Selective Somatostatin (SRIF) Agonists. 1. Lead Identification Using a Betide Scan

Journal of Medicinal Chemistry

Volumn 46, Issue 26, 2003, Pages 5579-5586

  Rivier, Jean ^a   Erchegyi, Judit ^a   Hoeger, Carl ^b   Miller, Charleen ^a   Low, William ^a   Wenger, Sandra ^c   Waser, Beatrice ^c   Schaer, Jean Claude ^c   Reubi, Jean Claude ^c  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; FORSKOLIN; OCTAPEPTIDE; PAPAIN; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN AGONIST; SOMATOSTATIN RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; DIASTEREOISOMER; ENZYMATIC DEGRADATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; NONHUMAN; SYNTHESIS;

ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; CELL LINE; CRICETINAE; CYCLIC AMP; HUMANS; LIGANDS; MEMBRANE PROTEINS; OLIGOPEPTIDES; PEPTIDES, CYCLIC; RADIOLIGAND ASSAY; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0346487260     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030243c     Document Type: Article

References (56)

1. Burgus, R.; Dunn, T.; Desiderio, D.; Ward, D.; Vale, W. W.; Guillemin, R. Characterization of the ovine hypothalamic hypophysiotropic TSH-releasing factor (TRF). Nature 1970, 226, 321-325.
2. Matsuo, H.; Baba, Y.; Nair, R. M.; Arimura, A.; Schally, A. V. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem. Biophys. Res. Commun. 1971, 43, 1334-1339.
3. Burgus, R.; Butcher, M.; Amoss, M.; Ling, N.; Monahan, M.; Rivier, J.; Fellows, R.; Blackwell, R.; Vale, W. W.; Guillemin, R. Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF). Proc. Natl. Acad. Sci. U.S.A. 1972, 69, 278-282.
4. Brazeau, P.; Vale, W. W.; Burgus, R.; Ling, N.; Butcher, M.; Rivier, J. E.; Guillemin, R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973, 179, 77-79.
5. Vale, W.; Spiess, J.; Rivier, C.; Rivier, J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science 1981, 213, 1394-1397.
6. Rivier, J.; Spiess, J.; Thorner, M.; Vale, W. Characterization of a growth hormone releasing factor from a human pancreatic islet tumor. Nature 1982, 300, 276-278.
7. Guillemin, R.; Brazeau, P.; Bohlen, P.; Esch, F.; Ling, N.; Wehrenberg, W. B. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982, 218, 585-587.
8. Koerber, S. C.; Rizo, J.; Struthers, R. S.; Rivier, J. E. Consensus bioactive conformation of cyclic GnRH antagonists defined by NMR and molecular modeling. J. Med. Chem. 2000, 43, 819-828.
9. Patel, Y. C.; Wheatley, T. In vivo and in vitro plasma disappearance and metabolism of somatostatin-28 and somatostatin-14 in the rat. Endocrinology 1983, 112, 220-225.
10. Bruno, J. F.; Xu, Y.; Song, J.; Berelowitz, M. Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11151-11155.
11. Yasuda, K.; Rens-Domiano, S.; Breder, C. D.; Law, S. F.; Saper, C. B.; Reisine, T.; Bell, G. I. Cloning of a novel somatostatin receptor, SSTR3, that is coupled to adenylyl cyclase. J. Biol. Chem. 1992, 267, 20422-20428.
12. Rohrer, L.; Raulf, F.; Bruns, C.; Buettner, R.; Hofstaedter, F.; Schule, R. Cloning and characterization of a fourth human somatostatin receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 4196-4200.
13. Xu, Y.; Song, H.; Bruno, J. F.; Berelowitz, M. Molecular cloning and sequencing of a human somatostatin receptor, hSSTR4. Biochem. Biophys. Res. Commun. 1993, 193, 648-652.
14. Yamada, Y.; Post, S. R.; Wang, K.; Medical, H.; Tager, S.; Bell, G. I.; Seino, S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 251-255.
15. Yamada, Y.; Reisine, T.; Law, S. F.; Ihara, Y.; Kubota, A.; Kagimoto, S. ; Seino, M.; Seino, Y.; Bell, G. I.; Seino, S. Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol. Endocrinol. 1992, 6, 2136-2142.
16. Yamada, Y.; Kagimoto, S.; Kubota, A.; Yasuda, K.; Masuda, K.; Someya, Y. ; Ihara, Y.; Li, Q.; Imura, H.; Seino, S.; Seino, Y. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and fifth (hSSTR5) human somatostatin receptor subtype. Biochem. Biophys. Res. Commun. 1993, 195, 844-852.
17. Patel, Y. C. Somatostatin and its receptor family. Front. Neuroendocrinol. 1999, 20, 157-198.
18. Brazeau, P.; Vale, W.; Burgus, R.; Ling, N.; Butcher, M.; Rivier, J.; Guillemin, R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973, 179, 77-79.
19. Guillemin, R.; Gerich, J. E. Somatostatin: physiological and clinical significance. Annu. Rev. Med. 1976, 27, 379-388.
20. Reichlin, S. Somatostatin. N. Engl. J. Med. 1983, 309, 1495-1501.
21. Reichlin, S. Somatostatin (second of two parts). N. Engl. J. Med. 1983, 309, 1556-1563.
22. Epelbaum, J. Somatostatin in the central nervous system: physiology and pathological modification. Prog. Neurobiol. 1986, 27, 63-100.
23. Sassolas, G. The role of Sandostatin in acromegaly. Metabolism: Clin., Exp. 1992, 41, 39-43.
24. Wynick, D.; Bloom, S. R. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J. Clin. Endocrinol. Metab. 1991, 73, 1-3.
25. Janecka, A.; Zubrzycka, M.; Janecki, T. Review: Somatostatin analogs. J. Pept. Res. 2001, 58, 91-107.
26. Schally, A. V.; Comaru-Schally, A. M.; Nagy, A.; Kovacs, M.; Szepeshazi, K.; Plonowski, A.; Varga, J. L.; Halmos, G. Hypothalamic hormones and cancer. Front. Neuroendocrinol. 2001, 22, 248-291.
27. Hannon, J. P.; Nunn, C.; Stolz, B.; Bruns, C.; Weckbecker, G.; Lewis, I. ; Troxler, T.; Hurth, K.; Hoyer, D. Drug design at peptide receptors: somatostatin receptor ligands. J. Mol. Neurosci. 2002, 18, 15-27.
28. de Herder, W. W.; Lamberts, S. W. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr. Opin. Oncol. 2002, 14, 53-57.
29. Rivier, J. E.; Hoeger, C.; Erchegyi, J.; Gulyas, J.; DeBoard, R.; Craig, A. G.; Koerber, S. C.; Wenger, S.; Waser, B.; Schaer, J.-C.; Reubi, J. C. Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1). J. Med. Chem. 2001, 44, 2238-2246.
30. Reubi, J. C.; Schaer, J.-C.; Wenger, S.; Hoeger, C.; Erchegyi, J.; Waser, B.; Rivier, J. SST3-selective potent peptidic somatostatin receptor antagonists. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 13973-13978.
31. 4-selective somatostatin (SRIF) agonists. 2. Analogues with β-methyl-3-(2-naphthyl)alanine substitutions at position 8. J. Med. Chem. 2003, 46, 5587-5596 (in this issue).
32. 4-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling. J. Med. Chem. 2003, 46, 5597-5605 (in this issue).
33. 4-selective somatostatin (SRIF) agonists. 4. Three-dimensional consensus structure by NMR. 2003, 46, 5606-5618 (in this issue).
34. Qasmi, D.; René, L.; Badet, B. An α-aminoglycine derivative suitable for solid phase peptide synthesis using Fmoc strategy. Tetrahedron Lett. 1993, 34, 3861-3862.
35. Sypniewski, M.; Penke, B.; Simon, L.; Rivier, J. (R)-tert-Butoxycarbonylamino-fluorenylmethoxycarbonyl-glycine from (S)-Benzyloxycarbonyl-serine or from papain resolution of the corresponding amide or methyl ester. J. Org. Chem. 2000, 65, 6595-6600.
36. Jiang, G.-C.; Simon, L.; Rivier, J. E. Orthogonally protected N-methyl-substituted α-aminoglycines. Protein Pept. Lett. 1996, 3, 219-224.
37. Jiang, G.; Miller, C.; Koerber, S. C.; Porter, J.; Craig, A. G.; Bhattacharjee, S.; Kraft, P.; Burris, T. P.; Campen, C. A.; Rivier, C. L.; Rivier, J. E. Betidamino acid scan of the GnRH antagonist Acyline. J. Med. Chem. 1997, 40, 3739-3748.
38. 7 substitutions. J. Med. Chem. 1999, 42, 761-768.
39. Rivier, J. E.; Jiang, G.-C.; Koerber, S. C.; Porter, J.; Craig, A. G.; Hoeger, C. Betidamino acids: Versatile and constrained scaffolds for drug discovery. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2031-2036.
40. Vale, W.; Rivier, C.; Brown, M.; Rivier, J. Pharmacology of TRF, LRF and somatostatin. Hypothalamic Peptide Hormones and Pituitary Regulation: Advances in Experimental Medicine and Biology; Plenum Press: New York, 1977; pp 123-156.
41. Vale, W.; Rivier, J.; Ling, N.; Brown, M. Biologic and immunologic activities and applications of somatostatin analogs. Metabolism 1978, 27, 1391-1401.
42. Kaljuste, K.; Undén, A. New method for the synthesis of N-methyl amino acids containing peptides by reductive methylation of amino groups on the solid phase. Int. J. Pept. Protein Res. 1993, 42, 118-124.
43. Reubi, J. C.; Schaer, J. C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J. S.; Mäcke, H. R. Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 2000, 27, 273-282.
44. 1-receptor subtype expressed by human tumors. Eur. J. Pharmacol. 1998, 345, 103-110.
45. Rohrer, S. P.; Birzin, E. T.; Mosley, R. T.; Berk, S. C.; Hutchins, S. M.; Shen, D.-M.; Xiong, Y.; Hayes, E. C.; Parmar, R. M.; Foor, F.; Mitra, S. W. ; Degrado, S. J.; Shu, M.; Klopp, J. M.; Cai, S.-J.; Blake, A.; Chan, W. W. S.; Pasternak, A.; Yang, L.; Patchett, A. A.; Smith, R. G.; Chapman, K. T.; Schaeffer, J. M. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998, 282, 737-740.
46. Bass, R. T.; Buckwalter, B. L.; Patel, B. P.; Pausch, M. H. P. L. A.; Strnad, J.; Hadcock, J. R. Identification and characterization of novel somatostatin antagonists. Mol. Pharmacol. 1996, 50, 709-715.
47. Bass, R. T.; Buckwalter, B. L.; Patel, B. P.; Pausch, M. H. P. L. A.; Strnad, J.; Hadcock, J. R. Identification and characterization of novel somatostatin antagonists. Mol. Pharmacol. 1997, 51, 170 Erratum.
48. Hocart, S. J.; Jain, R.; Murphy, W. A.; Taylor, J. E.; Morgan, B.; Coy, D. H. Potent antagonists of somatostatin: Synthesis and biology. J. Med. Chem. 1998, 41, 1146-1154.
49. Hocart, S. J.; Jain, R.; Murphy, W. A.; Taylor, J. E.; Coy, D. H. Highly potent cyclic disulfide antagonists of somatostatin. J. Med. Chem. 1999, 42, 1863-1871.
50. Rajeswaran, W. G.; Hocart, S. J.; Murphy, W. A.; Taylor, J. E.; Coy, D. H. Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist. J. Med. Chem. 2001, 44, 1305-1311.
51. Nutt, R. F.; Veber, D. F.; Curley, P. E.; Saperstein, R.; Hirschmann, R. Somatostatin analogs which define the role of the lysine-9 amino group. Int. J. Pept. Protein Res. 1983, 21, 66-73.
52. Stewart, J. M.; Young, J. D. Solid-Phase Peptide Synthesis. Solid-Phase Peptide Synthesis, 2nd ed.; Pierce Chemical Co.: Rockford, IL, 1984; p 176.
53. Miller, C.; Rivier, J. Peptide chemistry: Development of high-performance liquid chromatography and capillary zone electrophoresis. Biopolymers 1996, 40, 265-317.
54. Miller, C.; Rivier, J. Analysis of synthetic peptides by capillary zone electrophoresis in organic/aqueous buffers. J. Pept. Res. 1998, 51, 444-451.
55. Hoeger, C. A.; Galyean, R. F.; Boublik, J.; McClintock, R. A.; Rivier, J. E. Preparative reversed phase high performance liquid chromatography. II. Effects of buffer pH on the purification of synthetic peptides. Biochromatography 1987, 2, 134-142.
56. Schulz, S.; Pauli, S. U.; Handel, M.; Dietzmann, K.; Firsching, R.; Hollt, V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin. Cancer Res. 2000, 6, 1865-1874.